Hansabiomed OU (HBM) was established in May 2007 with Estonian and Italian private capitals. The owners of HBM include leading scientists at an international level, the inventors of HBM patents and a high quality management. Our major focus is on translational research in exosome based diagnostics of cancer and neurodegenerative diseases.

Global Strategy
HBM performs discovery and pre-clinical development of new diagnostic tools having their main focus on a proprietary exosome based ELISA platform called EXOTEST. HBM is currently testing and validating his EXOTEST platform in different cancers and neurodegenerative diseases including Alzheimer, Parkinson and ALS. Our pipeline also includes newly discovered tumor antigens and targets currently under validation. HBM global strategy is to perform preclinical development in-house and out-license or spinn-out IP to major Pharma Companies or NewCo for clinical development and validation and marketing. In addition to internal research and discovery, HBM also scouts for interesting new ideas in the biomedical field, and considers opportunities for patenting or in-licensing highly innovative research performed by independent academic researchers. Our believe and policy is to invest in brain and innovation, and we devote to this activity the larger part of our financial resources and incomes.

Team and Partners
Beside Management, our team today consists of 15 scientists and administrative staff, all of them highly qualified and motivated people. Our labs are located in Tehnopol, the Tallinn Technology Park. We have many Academic and non Academic collaborations with different research groups all over the world.

Antonio Chiesi, MD
Founder and CEO